Keywords: Novartis, Gilenya, Multiple sclerosis, EMA, Interferon beta, Biosimilars

EMA starts review of Gilenya; guidance on biosimilar interferon beta

Article | 23 January 2012

Print This

The European Medicines Agency has begun a review of the benefits and risks of Swiss drug major Novartis’ (NOVN: ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in